Suboxone (buprenorphine) and methadone are the two leading medications available for the treatment of opioid addiction. They are both opioid replacement therapies that, when taken regularly, will prevent an individual from experiencing opioid withdrawal sickness. Suboxone was approved by the FDA in 2002, and this allowed local physicians to begin prescribing Suboxone from their offices to opioid addicted patients seeking help.
This was a landmark achievement in consumer choice and provided people another very useful option for dealing with opioid addiction. To treat a patient with suboxone, a physician must first complete a comprehensive course, and become approved, before being allowed to prescribe the medication.
Since opioid replacement medication by itself addresses only the underlying physiological dependence (but not the related psychological contributors to addiction), patients are required to obtain substance abuse counseling as a part of their suboxone treatment. This additional requirement helps to ensure that patients are receiving education & training in understanding their addiction, and in identifying methods for preventing opioid relapse in the future.
Many suboxone-approved physicians do not provide this supplemental addiction counseling, and will consequently refer their suboxone patients to local providers who offer drug treatment services.
While suboxone and methadone are similar in action, they are unique enough to offer distinctly different advantages. You can review our comparison chart to examine some of the differences between the two medications. Both methadone and suboxone are slow acting, long lasting opioid agonists that bind to the body's opiate receptors. This particular action eliminates opioid withdrawal sickness very effectively, and thus allows individuals to resume their daily lives.
Suboxone is actually a branded medication & product of the pharmaceutical company, Reckitt Benckiser. Suboxone is currently available as a thin film that is held under the tongue until the medication dissolves. Once dissolved, the medication is naturally absorbed through the tissues under the tongue and into the bloodstream. The newer film formulation dissolves somewhat more quickly than the previously available tablet form.
Suboxone is generally taken once per day although some patients with a milder opioid dependency may be able to take the medication every other day and remain comfortable. Suboxone does not produce a drug high for tolerant users, and does not interfere with one's daily activities. Many patients report feeling very comfortable while being maintained on suboxone and also during their gradual taper off of the medication.
What is in Suboxone?
Suboxone is a combination of buprenorphine and naloxone. Buprenorphine (an opioid agonist) is the ingredient that binds to opiate receptors and provides relief by blocking withdrawal symptoms (very similar to methadone). Naloxone is an opioid antagonist that reverses the effects of opiates and will cause withdrawal. This seems like a strange paradox having both ingredients in one tablet. However, do not worry. Remember, Suboxone is dissolved and absorbed under the tongue. The antagonist, Naloxone, becomes inert (has no effect) when dissolved under the tongue. So one only experiences the benefit of the Buprenorphine.
Why is Naloxone Added to Suboxone?
Specifically to discourage & prevent injection use of suboxone. Some addicted individuals may try to inject suboxone to obtain a drug high. When they do so, the Naloxone becomes immediately active (since it's being injected directly into the bloodstream), and it brings on sudden withdrawal symptoms making the individual feel very sick. This reinforces a person for using suboxone the proper way (under the tongue), and prevents future attempts at injecting suboxone.
How Do I Know if Suboxone is Right For Me?
This is a great question although a little difficult to answer. Suboxone tends to be effective for a considerable number of people addicted to opioids. Many of those who do well with suboxone are people who have a relatively shorter duration of opioid addiction or whose addiction is based on a comparatively smaller amount of daily opioid use. Heavy opioid users with a longer history of addiction sometimes respond better to methadone. However, there are notable exceptions.
Suboxone has a ceiling effect around 24-32 mg of medication daily. 32 mg is generally considered to be the dose at which maximum withdrawal relief is provided. For most addicted people, taking more than 24-32 mg of suboxone daily will not provide any more additional relief. Methadone has no such ceiling effect and its dosage levels can be raised much higher, consequently providing a greater level of comfort and symptom relief for more severe opioid dependencies.
In conclusion, 8 mg to 32 mg of suboxone may provide excellent relief for someone new to medication-assisted recovery. If they find that suboxone is not strong enough to manage their withdrawal symptoms, then methadone most certainly will since it has no "ceiling effect".
Taper programs aim to stabilize an opioid addicted individual on suboxone for a brief period of time and then taper their dosage down over a 60 to 90 day period. This taper period is not set in stone and can vary depending on the individual's need. The primary goal is to stabilize with suboxone and to then taper off with the end result being complete freedom from opioids and opioid replacement medication. Some patients do very well with a scheduled taper. Other patients may find that tapering is problematic and will switch to a period of maintenance. Maintenance with suboxone is effective and safe, just like with methadone. Upon first entering the market, Suboxone was mostly used for tapering off of opioids. However, it is commonly used today for extended maintenance in similar fashion to methadone.
For more on Suboxone Doctors, read: www.Methadone.us/suboxone-doctors/
The U.S. House of Representatives just passed a sweeping reform, called the 21st Century Cures Act, that will infuse $1 billion in new funding earmarked for opioid treatment and prevention services.
It has taken several years of alarming statistics on the national opioid epidemic, but Congress has responded. This USA Today article provides an overview of the numbers. In addition to the $1 billion for opioid services will be another $4.8 billion for cutting-edge research around treating Alzheimers, cancer, traumatic brain injury, and other medical issues.
The bill received enormous bipartisan support and passed 392-to-26. In 2016, death by drug overdose surpassed death by car crashes and gun fatalities. The public outcry for government intervention has been steady. With so many families having been affected by addiction issues, the new funding allowance should open doors for opioid treatment particularly in rural areas where opioid services have been severely lacking.
Methadone remains the #1 medication-assisted treatment option. Buprenorphine medications are; however, making a big impact in the treatment field with a wide variety of buprenorphine-based formulations coming to market. In addition to the familiar suboxone film, are probuphine (a buprenorphine implant), subutex (an uncoated buprenorphine tablet), and bunavail.
Buprenorphine.US is the newly developed companion website to Methadone.US. Methadone has been in use as an opioid addiction treatment medication for nearly 50 years. In 2002, buprenorphine became available in the U.S. as a new alternative for people suffering with opioid addiction. Since then, various medications containing buprenorphine have been released such as suboxone and zubsolv.
Buprenorphine for opioid addiction treatment can only be prescribed by qualified physicians who have received training on the proper use of buprenorphine. As the opioid addiction problem grew over the last 15 years, many thousands of doctors pursued training and were approved in the use of buprenorphine-based medications to treat opiate addiction.
At Methadone.US, we have served over 1 million U.S. visitors since the website’s launch in 2011. Buprenorphine.US will aim to connect many more individuals with qualified physicians who can help them in their journey toward a genuine recovery and improved quality of life.
There are currently well over 1000 methadone clinics in operation across the United States and many more throughout the world. Methadone has been a leading treatment intervention for opioid addiction for more than 40 years. Methadone is an FDA-approved medication and it’s use in treating opioid addiction has been identified by SAMHSA as a best practice, evidence-based treatment approach.
Adding to the legacy of methadone as a successful treatment medium are the hundreds of thousands of individuals who have been able to totally eliminate the severe opioid withdrawal sickness that wrecked their lives. The value of this medical benefit is priceless.
The cost for participating in a methadone program varies from clinic to clinic and in part depends on whether the clinic receives any state funding or accepts Medicaid for payment. Many clinics operate as private practices funded primarily through patient self-payment. Private clinics often offer a substantial discount for patients that pay for a month of services in advance.
Due to methadone’s proven efficacy, many addicted people experience rapid relief from opiate withdrawal and find themselves eating and sleeping more normally, gaining weight, and able to work again. They are able to pursue other goals & responsibilities that had previously become too difficult in their active addiction.
Methadone is a powerful medication that must be taken as prescribed and in conjunction with good counseling. When a patient is willing to embrace medication-assisted treatment and to utilize it properly, recovery can happen. This life restoration process is demonstrated on a daily basis all around the country.
It was announced in June that North Dakota would be receiving its first methadone clinic. North Dakota and Wyoming are the only two states in the U.S. that have yet to provide a methadone treatment program for opioid addiction.
The region has suffered in recent years with an increase in the use of heroin and fentanyl, and with associated opioid overdoses. Kurt Snyder is the Executive Director of the new clinic, Heartview Foundation. Mr. Snyder echoed the research-based evidence showing that medication-assisted treatment for opioid addiction provides superior results to abstinence-only treatment interventions.
In the article linked above from The Jamestown Sun, a local police detective indicated that the addiction problem had recently worsened in North Dakota as a result of the price of drugs dropping.
The Heartview Foundation clinic will also offer buprenorphine and naloxone in addition to methadone thus providing a more complete range of medication assisted therapies. Therapeutic counseling and mental health treatment will be a component of the Heartview program as well as drug testing.
Of particular benefit too is the recent initiative in North Dakota that will allow pharmacists the ability to prescribe naloxone so that opioid overdoses can hopefully be greatly reduced. The ready accessibility of naloxone is receiving a nationwide push as communities struggle to address overdose concerns.
Methadone.US welcomes a new addition to the featured clinics here on the site with the listing of BrookStone Medical Center in St. George, Utah.
The FDA has approved a new implantable drug called Probuphine. Probuphine contains the partial opioid agonist, buprenorphine, which is used to suppress the opioid withdrawal symptoms that interfere with daily life.
The implant is the size of a matchstick and is inserted under the skin in the forearm area. It steadily releases a dose of buprenorphine which has been scientifically proven an effective treatment for eliminating opiate withdrawal symptoms in a number of people physically dependent on opioids.
With heroin and opioid overdose deaths at an all time high in the United States, this new alternative offers one more beneficial path for anyone struggling with opioid relapse and chronic withdrawal. Importantly, Probuphine only treats the physical withdrawal from opioids such that the underlying psychological factors of addiction must still be treated through counseling and other support approaches.
The Wall Street Journal has an extensive article on this new medication and the historically important role of methadone and oral buprenorphine. In the article, Nora Volkow (director of the National Institute on Drug Abuse) is quoted as saying:
Over 47,000 people died in the U.S. of drug overdoses in 2014. A majority of these were attributed to heroin and prescription painkillers. With continued coverage in the media and ongoing community discussion, more answers and helpful interventions will hopefully see the light of day.